The Aesthetic Guide is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Candela expands portfolio with acquisition of Ellipse

Article-Candela expands portfolio with acquisition of Ellipse


Candela Corporation (Irvine, California, U.S.) has been at the forefront of the aesthetic industry in one form or another for decades. Originally centered primarily around the laser market, as its Candela moniker suggests, the company experienced an exponential leap forward in technology and presence when it merged with Syneron Medical, Ltd. in 2010. Now, with the recent acquisition of Ellipse (Hørsholm, Denmark), the company has additionally expanded and deepened its portfolio of top energy-based medical devices.

“As a physician who utilizes the Ellipse IPL platform and considers it a foundational technology for all dermatology practices, I am pleased that Candela can now offer the full spectrum of light, laser and energy-based solutions to physicians and patients worldwide,” said board certified dermatologist Jill Waibel, M.D., founder and medical director of Miami Dermatology and Laser Institute in Miami, Florida, U.S.

Candela announced the acquisition of Ellipse, known for excellent laser- and light-based medical devices, in September 2018. Bolstering an already impressive footprint in the multi-application space, Ellipse technology complements Candela’s current array of devices, according to Geoffrey Crouse, chief executive officer at Candela.

RELATED: UltraShape Power and VelaShape III remain standard for body contouring

“This acquisition means that we can provide our customers with a truly comprehensive portfolio. Candela’s best-in-class laser and energy-based technologies are now coupled with a trusted, well-respected IPL technology,” he said. “Ellipse platforms will enable us to further provide aesthetic practices with fully-scalable multi-technology, multi-application capability.”

“For physicians and patients worldwide, our brand promise is ‘Science, Results, Trust,’ and we are delivering on that promise by bringing Ellipse under our umbrella and strengthening our portfolio,” Mr. Crouse continued. “The Ellipse product portfolio is consistent with our commitment to scientifically proven technologies backed by consistent clinical outcomes.”

Heading the strong Ellipse product line is Nordlys, a multi-application, multi-technology platform combining Ellipse IPL and 1064 nm Nd:YAG laser modalities for vascular and pigmented lesions, as well as hair removal. Reliable and easy to operate, Nordlys also features a fractionated 1550 nm handpiece for skin resurfacing, making it more versatile and truly representative of a ‘practice-building platform’ with high ROI. Safety is ensured by onboard automatic parameter selection capability.

Other standout Ellipse products include an IPL-only system used for skin rejuvenation, facial veins and hair removal (Sirius), and a small and highly-flexible fractional non-ablative laser system used for skin resurfacing (Ydun). Ellipse IPL uses unique selective waveband technology with dual filtering on all IPL handpieces to focus on effective wavelengths and selectively deliver precise energy to the targeted area, using sub-millisecond pulses for some applications.

“We are excited to join forces with Candela and market our strong technology platforms via Candela’s expansive global footprint, along with its commitment to clinical excellence, quality and innovation,” said Jacob Kildegaard Larsen, chief executive officer at Ellipse.

“Candela and Ellipse are both physician-acknowledged leaders in their respective categories,” added Christine Dierickx, M.D., a dermatologist specializing in laser surgery and cosmetic dermatology, and medical director of Skinperium in Luxembourg. “Bringing the companies together will herald a new era in device innovation that elevates patient care.”